Health Discovery Corporation (OTCBB: HDVY), the molecular diagnostics company that recently launched MelApp, the first SVM-based image analysis iPhone app for melanoma risk assessment, reports great adoption among consumers with nearly 5000 downloads across 48 countries in just its first two months on the market with the second month growth rate being more than 35% higher than the first month. Pleased with the interest from consumers and the medical community to date, Health Discovery is now preparing to release a version of MelApp for the increasingly popular Android operating system expected around the first week of October. “It’s incredibly exciting to see our advanced mathematical techniques used in this manner, but more so, to see the volume of downloads after only an initial soft launch of the MelApp. The initial success of MelApp exceeds our expectations,” said Stephen D. Barnhill, M.D., Chairman and CEO of Health Discovery Corporation. “Management is quite pleased with the initial volume of downloads and is committed to MelApp’s next stage of growth with an improved iPhone update and the forthcoming Android application. Once the Android version of MelApp is launched, the Company plans a much more aggressive international marketing program and expects downloads to increase significantly in the upcoming months.” Launched this summer, MelApp uses highly sophisticated patent protected mathematical algorithms and image based pattern recognition technology to analyze an uploaded image. The app was validated using an image database licensed from Johns Hopkins University Medical Center and uses the iPhone camera feature to deliver a risk analysis of user’s photographed skin lesions within seconds. In addition, MelApp can use the iPhone GPS to refer users to physicians specializing in the diagnosis and treatment of melanoma for proper medical follow-up. “We are also quite pleased with the number of both academic and private practice U.S. and International physicians specializing in melanoma diagnosis and treatment that have requested to be part of our subscribed physician referral network.” Dr. Barnhill adds, "It has been hugely rewarding to recently hear of a patient being diagnosed with early stage melanoma after being referred to a physician by MelApp."
Created for iPhone, iPod touch and iPad, MelApp’s latest update is now available to current users. New users can download the app from the iTunes App Store at a special limited time price of $1.99. MelApp will be available on the Android Market around the first week of October also for an introductory price of $1.99.Physicians who diagnose and treat melanoma can become a subscribing member of HDC’s physician referral network by contacting firstname.lastname@example.org. About MelApp & Health Discovery Corporation MelApp uses highly sophisticated patent protected mathematical algorithms and image based pattern recognition technology to analyze the uploaded image. MelApp was validated using an image database licensed from Johns Hopkins University Medical Center and uses the iPhone camera feature to deliver a risk analysis of user’s photographed skin lesions within seconds. The app can use the iPhone GPS to refer users to physicians specializing in the diagnosis and treatment of melanoma for proper medical follow-up. MelApp by Health Discovery Corporation was launched at a special limited time introductory price of $1.99 and is available in the iTunes App Store. For more complete details, visit http://www.melapp.net, http://www.facebook.com/MelApp or http://twitter.com/#!/SafeHealthApps. Health Discovery Corporation is a molecular diagnostics company that uses advanced mathematical techniques to analyze large amounts of data to uncover patterns that might otherwise be undetectable. It operates primarily in the emerging field of personalized medicine where such tools are critical to scientific discovery. Its primary business consists of licensing its intellectual property and developing its own product line of biomarker-based diagnostic tests that include human genes and genetic variations, as well as gene, protein, and metabolic expression differences and image analysis in digital pathology and radiology. For more information, see www.healthdiscoverycorp.com. Forward-Looking Statements This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, the accuracy of which is necessarily subject to risks and uncertainties, including, without limitation, statements regarding future performance, opportunities and investments, and anticipated results in general. From time to time the Company may make other forward-looking statements in relation to other matters, including without limitation, commercialization plans and strategic partnerships. Actual results may differ materially due to a variety of factors, including, among other things, the acceptance of our approach to applying mathematics, computer science and physics into the disciplines of biology, organic chemistry and medicine and our products and technologies associated with those approaches, the ability to develop and commercialize new drugs, therapies or other products based on our approaches, and other factors set forth from time to time in the Company’s Securities and Exchange Commission filings.
All forward-looking statements and cautionary statements included in this document are made as of the date hereof based on information available to the Company as of the date hereof, and the Company assumes no obligation to update any forward-looking statement or cautionary statement.